JP2018527383A5 - - Google Patents

Info

Publication number

JP2018527383A5

JP2018527383A5 JP2018514409A JP2018514409A JP2018527383A5 JP 2018527383 A5 JP2018527383 A5 JP 2018527383A5 JP 2018514409 A JP2018514409 A JP 2018514409A JP 2018514409 A JP2018514409 A JP 2018514409A JP 2018527383 A5 JP2018527383 A5 JP 2018527383A5

Authority

JP

Japan

Prior art keywords

composition according

item

composition

immune complex

administered

Prior art date

2016-09-16

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 82
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 63
• 239000003795 chemical substances by application Substances 0.000 claims description 59
• 229910052697 platinum Inorganic materials 0.000 claims description 41
• 229960004679 doxorubicin Drugs 0.000 claims description 32
• 206010028980 Neoplasm Diseases 0.000 claims description 24
• 229960000397 bevacizumab Drugs 0.000 claims description 24
• 201000011510 cancer Diseases 0.000 claims description 24
• 229960004562 carboplatin Drugs 0.000 claims description 23
• 190000008236 carboplatin Chemical compound 0.000 claims description 23
• 238000003364 immunohistochemistry Methods 0.000 claims description 21
• 229940046159 pegylated liposomal doxorubicin Drugs 0.000 claims description 21
• 102000010451 Folate receptor alpha Human genes 0.000 claims description 15
• 108050001931 Folate receptor alpha Proteins 0.000 claims description 15
• 229940079593 drug Drugs 0.000 claims description 15
• 239000003814 drug Substances 0.000 claims description 15
• 239000000427 antigen Substances 0.000 claims description 11
• 102000036639 antigens Human genes 0.000 claims description 11
• 108091007433 antigens Proteins 0.000 claims description 11
• 239000012634 fragment Substances 0.000 claims description 11
• 206010033128 Ovarian cancer Diseases 0.000 claims description 9
• 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 8
• 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims description 8
• 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims description 8
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 6
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 4
• 206010014733 Endometrial cancer Diseases 0.000 claims description 4
• 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
• 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims description 4
• 229940127121 immunoconjugate Drugs 0.000 claims description 4
• 201000002628 peritoneum cancer Diseases 0.000 claims description 4
• 150000003431 steroids Chemical class 0.000 claims description 4
• FUHCFUVCWLZEDQ-UHFFFAOYSA-N 1-(2,5-dioxopyrrolidin-1-yl)oxy-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid Chemical compound O=C1CCC(=O)N1OC(=O)C(S(=O)(=O)O)CCSSC1=CC=CC=N1 FUHCFUVCWLZEDQ-UHFFFAOYSA-N 0.000 claims description 3
• 201000001342 Fallopian tube cancer Diseases 0.000 claims description 3
• 208000013452 Fallopian tube neoplasm Diseases 0.000 claims description 3
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
• 201000005202 lung cancer Diseases 0.000 claims description 3
• 208000020816 lung neoplasm Diseases 0.000 claims description 3
• 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 2
• 230000037396 body weight Effects 0.000 claims description 2
• 230000002357 endometrial effect Effects 0.000 claims description 2
• 238000009093 first-line therapy Methods 0.000 claims description 2
• 230000002611 ovarian Effects 0.000 claims description 2
• 210000003101 oviduct Anatomy 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims description 2
• 238000009094 second-line therapy Methods 0.000 claims description 2
• 238000009095 third-line therapy Methods 0.000 claims description 2
• 239000000203 mixture Substances 0.000 claims 48
• 125000003275 alpha amino acid group Chemical group 0.000 claims 6
• 239000013612 plasmid Substances 0.000 claims 2
• 238000002560 therapeutic procedure Methods 0.000 claims 2
• 239000003889 eye drop Substances 0.000 claims 1
• 238000000034 method Methods 0.000 description 109
• ZOHXWSHGANNQGO-DSIKUUPMSA-N 1-amino-4-[[5-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-2-methyl-5-oxopentan-2-yl]disulfanyl]-1-oxobutane-2-sulfonic acid Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCCC(C(N)=O)S(O)(=O)=O)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ZOHXWSHGANNQGO-DSIKUUPMSA-N 0.000 description 9
• 229960004316 cisplatin Drugs 0.000 description 6
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 6
• 108091008601 sVEGFR Proteins 0.000 description 6
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 6
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 6
• 150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 description 6
• 230000001988 toxicity Effects 0.000 description 4
• 231100000419 toxicity Toxicity 0.000 description 4
• XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical group COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 3
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 3
• 239000002147 L01XE04 - Sunitinib Substances 0.000 description 3
• 239000005511 L01XE05 - Sorafenib Substances 0.000 description 3
• 239000003798 L01XE11 - Pazopanib Substances 0.000 description 3
• 229960002833 aflibercept Drugs 0.000 description 3
• 108010081667 aflibercept Proteins 0.000 description 3
• 229960003005 axitinib Drugs 0.000 description 3
• RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 3
• 229960002412 cediranib Drugs 0.000 description 3
• 229960000639 pazopanib Drugs 0.000 description 3
• CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 3
• 229960003787 sorafenib Drugs 0.000 description 3
• 229960001796 sunitinib Drugs 0.000 description 3
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 3
• 101710112752 Cytotoxin Proteins 0.000 description 2
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
• 231100000599 cytotoxic agent Toxicity 0.000 description 2
• 239000002619 cytotoxin Substances 0.000 description 2
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
• 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
• 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
• 108091008605 VEGF receptors Proteins 0.000 description 1
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 208000016992 lung adenocarcinoma in situ Diseases 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1